Literature DB >> 34643914

Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Paul J Converse1, Deepak V Almeida2, Eric L Nuermberger2.   

Abstract

Great progress has been made in understanding the pathogenesis and treatment of Buruli ulcer over the last 20 years. The rediscovery of the mouse footpad model of the disease with translation to clinical practice has changed treatment of this infectious disease, caused by Mycobacterium ulcerans, from surgery and skin grafting to the administration of antibiotics for 8 weeks or less with superior cure rates. Here we describe the development and enhancement of the mouse model during the last two decades.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Buruli ulcer; Mycobacterium ulcerans

Mesh：

Substances：

Year:  2022        PMID： 34643914      PMCID： PMC8996816          DOI： 10.1007/978-1-0716-1779-3_19

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  34 in total

1.  The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo.

Authors:  F FENNER
Journal:  Am Rev Tuberc       Date:  1956-05

Review 2.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

Review 3.  Using animal models to develop new treatments for tuberculosis.

Authors:  Eric Nuermberger
Journal:  Semin Respir Crit Care Med       Date:  2008-09-22       Impact factor: 3.119

4.  Shortening Buruli Ulcer Treatment with Combination Therapy Targeting the Respiratory Chain and Exploiting Mycobacterium ulcerans Gene Decay.

Authors:  Paul J Converse; Deepak V Almeida; Sandeep Tyagi; Jian Xu; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-06-24       Impact factor: 5.191

5.  Immunogenicity of Mycobacterium ulcerans Hsp65 and protective efficacy of a Mycobacterium leprae Hsp65-based DNA vaccine against Buruli ulcer.

Authors:  Emmanuelle Coutanceau; Pierre Legras; Laurent Marsollier; Gilles Reysset; Stewart T Cole; Caroline Demangel
Journal:  Microbes Infect       Date:  2006-05-24       Impact factor: 2.700

6.  Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans.

Authors:  K M George; L P Barker; D M Welty; P L Small
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

7.  Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Jérome Robert; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

8.  BCG-mediated protection against Mycobacterium ulcerans infection in the mouse.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset
Journal:  PLoS Negl Trop Dis       Date:  2011-03-15

9.  Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy.

Authors:  Tianyu Zhang; Si-Yang Li; Eric L Nuermberger
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

10.  Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease.

Authors:  Paul J Converse; Yalan Xing; Ki Hyun Kim; Sandeep Tyagi; Si-Yang Li; Deepak V Almeida; Eric L Nuermberger; Jacques H Grosset; Yoshito Kishi
Journal:  PLoS Negl Trop Dis       Date:  2014-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.